Bristol-Myers Squibb-Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates

Financial Performance - Bristol Myers Squibb reported quarterly earnings of $1.80 per share, exceeding the Zacks Consensus Estimate of$ 1.51 per share, compared to a loss of $4.40 per share a year ago, representing an earnings surprise of 19.21% [1] - The company posted revenues of$ 11.2 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 4.38%, although this is a decrease from year-ago revenues of $11.87 billion [2] - Over the last four quarters, Bristol Myers has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Bristol Myers shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has decreased by 8.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is$ 1.69 on revenues of $11.35 billion, and for the current fiscal year, it is$ 6.76 on revenues of $45.82 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]